A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer	HER2-positive Breast Cancer	Recruiting	Phase 3	2026-06-29		NCT07673029

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
GeneQuantum Healthcare (Suzhou) Co., Ltd.	3

70 results · Page 1 of 3

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Anhui Cancer Hospital	Hefei	China	8
Anyang Cancer Hospital	Anyang	China	7
Chongqing University Cancer Hospital	Chongqing	China	54
Deyang People's Hospital	Deyang	China	4
Fudan University Shanghai Cancer Center	Shanghai	China	257
Fujian Cancer Hospital	Fuzhou	China	109
Ganzhou Cancer Hospital	Ganzhou	China	3
Guangxi Medical University Cancer Hospital	Nanning	China	24
Guizhou Medical University Cancer Hospital	Guiyang	China	1
Guizhou Provincial People's Hospital	Guiyang	China	24
Harbin Medical University Cancer Hospital	Harbin	China	102
Henan Cancer Hospital	Zhengzhou	China	67
Hubei Cancer Hospital	Wuhan	China	95
Hunan Cancer Hospital	Changsha	China	123
Liaoning Cancer Hospital	Shenyang	China	15
Linyi Cancer Hospital	Linyi	China	10
Linyi Central Hospital	Linyi	China	1
Luoyang Central Hospital	Luoyang	China	5
Meizhou People's Hospital	Meizhou	China	2
Nanchang People's Hospital	Nanchang	China	1
Renji Hospital, School of Medicine, Shanghai Jiao Tong University	Shanghai	China	16
Renmin Hospital of Wuhan University	Wuhan	China	42
Shandong Cancer Hospital	Jinan	China	86
Shanghai Gaobo Cancer Hospital	Shanghai	China	1
Shantou Central Hospital	Shantou	China	6

Clinical trials